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Background: Spinal cord lesions is one of the predominant characteristics in patients with neuromyelitis optica
spectrum disorders (NMOSD). Interestingly, mounting evidence indicates that spinal cord atrophy (SCA) is one of
common clinical features in multiple sclerosis (MS) patients, and correlates closely with the neurological disability.
However, Clinical studies related to the SCA aspects of NMOSD are still scarce.
Methods: We retrospectively analyzed 185 patients with NMOSD, including 23 patients with SCA and 162 patients
without SCA. Data were collected regarding clinical characteristics, laboratory tests, and magnetic resonance
imaging findings.
Results: 12.4% of patients had SCA in NMOSD. Patients with SCA had a longer disease duration and higher EDSS at
clinical onset and last visit. More importantly, SCA patients were more prone to reach disability milestones (EDSS≥ 6.0).
Bowel or bladder dysfunction, movement disorders, and sensory disturbances symptoms were more common in
patients with SCA. ESR and CRP were significantly higher in patients with SCA than those without SCA. Patients with
SCA were more frequently complicated with cervical cord lesions. However, the ARR, progression index, seropositive
rate of NMO-IgG and OCB were similar in the two groups. Futhermore, LETM did not differ significantly between
patients with SCA and without SCA in NMOSD patients.
Conclusions: Patients with SCA might have longer disease duration, more severe clinical disability, and more
frequently complicated with cervical spinal cord lesions. SCA might be predictive of the more severe neurologic
dysfunction and worse prognosis in NMOSD. Inflammation contributes to the development of SCA in NMOSD.
Keywords: Neuromyelitis optica spectrum disorders, Spinal cord atrophy, Longitudinally extensive transverse myelitis,
Magnetic resonance imagingBackground
Neuromyelitis optica spectrum disorders (NMOSD) is a
group of inflammatory demyelinating disorders, mediated
by pathogenic autoantibodies (NMO-IgG) against astrocyte
aquaporin-4 (AQP4), the main water channel of the central
nervous system (CNS) [1,2]. As it is well known that the
spinal cord is one of the most frequently involved sites in
NMOSD, especially longitudinally extensive spinal cord* Correspondence: luzhqidoctor@126.com
†Equal contributors
1Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital
of Sun Yat-sen University, No 600 Tianhe Road, Guangzhou, Guangdong 510630,
China
Full list of author information is available at the end of the article
© 2014 Wang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.lesions have been observed in 72.4-100% of NMO [3-6],
and are predominantly located in the cervical and upper
thoracic region. Futhermore, the neurological function
changes in spinal cord injury are considered as the clinical
hallmark of the disease evolution [5,6].
The current studies indicate atrophy is a common pat-
tern during the disease course and a potential marker of
clinical disability in all subtypes of multiple sclerosis (MS)
[7-9]. Spinal cord atrophy (SCA), particularly atrophy of
cervical cord, is considered to contribute to accumulation
of disability and clinical outcome [7,10]. SCA is expected to
present in NMOSD. However, little attention has been paid
to exploring the clinical features of SCA in NMOSD. OnlyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographic and clinical characteristics of
patients with or without SCA in NMOSD
NMOSD with
SCA (n = 23)
NMOSD without
SCA (n = 162)
P
Gender, F:M 19:4 133:29 0.952
Age, years 46.82 ± 11.17 42.05 ± 11.52 0.064
Age at onset, years 35.84 ± 13.99 38.49 ± 12.05 0.335
Disease duration, years 7.92 (0.5-30) 1.75 (0–39) 0.001**
SCA duration, years 4.58 (0.6-26)
Annualized relapse rate 0.84 (0.07-3.23) 0.66 (0–12) 0.826
EDSS at clinical onset 6.02 ± 2.16 2.49 ± 2.01 0.001**
EDSS > 6 (at clinical onset) 14 (60.9%) 14 (8.6%) 0.001**
EDSS at last visit 5.37 ± 2.38 4.21 ± 1.80 0.006*
EDSS > 6 (at last visit) 11 (47.8%) 27 (28.9%) 0.001**
Reaching EDSS 6 from
onset, n (%)
15 (65.62%) 30 (18.2%) 0.001**
Reaching EDSS 6 duration
from onset, years
1 (0.08-6) 2.25 (0.08-23.08) 0.001**
Progression index 0.79 (0.14-12) 0.96 (0–90) 0.410
Clinical features, n (%)
Headache 4 (17.4%) 21 (13%) 0.561
Dizziness 3 (13%) 23 (14.2%) 0.882
Nystagmus 4 (17.4%) 15 (9.3%) 0.229
IHN 6 (26.1%) 43 (26.5%) 0.963
Dysphagia or choking
cough
3 (13%) 12 (7.4%) 0.354
Bowel or bladder
dysfunction
16 (69.6%) 59 (36.4%) 0.002**
Visual impairment 19 (82.6%) 131 (80.9%) 0.842
Movement disorders 22 (95.7%) 82 (50.6%) 0.001**
Sensory disturbances 21 (91.3%) 112 (69.1%) 0.027*
Neuropathic pain 8 (34.8%) 54 (33.3%) 0.890
Early standard corticosteroid
therapy (<7 days of onset)
9 (39.1%) 128 (70.01%) 0.0539
NMOSD = neuromyelitis optica spectrum disorders; SCA = spinal cord atrophy;
ARR = Annualized relapse rate; EDSS = Expanded Disability Status Scale;
IHN = intractable hiccup and nausea; SCA duration = Duration between at the
onset of NMOSD and at the appearance of SCA; *P < 0.05; **P < 0.01; P values
also reflect comparison of percentages in clinical features.
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rence, locations of the SCA in exploring the features of
spinal cord lesions with NMO patients [4,11-13]. Therefore,
we investigated and compared the clinical, laboratory, and
magnetic resonance imaging (MRI) characteristics between
NMOSD with and without SCA.
Methods
Patients
We retrospectively reviewed the medical records of 185
patients with NMOSD (23 patients with SCA and 162
patients without SCA) who were hospitalized at the
multiple sclerosis (MS) center of the Third affiliated
hospital of Sun Yat-sen University between March
2008 and September 2013. All the patients were diagnosed
according to the Wingerchuk 2006 and 2007 criteria
[1,6,14,15]. And followed up in the outpatient once a
month after discharge. Disability was assessed using the
Expanded Disability Status Scale (EDSS), EDSS milestones
(severe disability) at follow-up was defined as EDSS ≥ 6.0
[16,17]. Disease severity was evaluated by the progression
index (Progression index = EDSS/disease duration) [18].
Relapses were defined as new or recurrent neurologic
symptoms not associated with fever or infection that
lasted ≥24 h and were accompanied by new neurologic
signs found by the examining neurologist. Disease dur-
ation as measured in years since the onset of the first
symptoms until last follow up, disease activity such as
ARR (ARR = total number of relapses/disease duration)
and total number of relapses [19,20]. Cerebrospinal fluid
oligoclonal bands (OCBs), NMO-IgG, anti-nuclear anti-
bodies (ANA), anti-SSA/Ro antibodies (SSA), anti-SSB/La
antibodies (SSB), rheumatoid factor (RF), complement,
ESR, CRP were tested at the time of the initial diagnosis,
prior to corticosteroid treatment. All of the patients re-
ceived high-dose corticosteroids pulses [(methylpredniso-
lone 1 g, IV/d for 5d) for 2–3 courses, each treatment
interval was three days] during the relapse period. And in
remission period, all the patients are treated with oral
small doses of prednisone (8–20 mg/d, oral) combined
with azathioprine (50–100 mg/d). None of the patients
had underwent therapeutic plasmapheresis. The patients
were excluded who had anemia, hypoalbuminemia, infec-
tious diseases, vascular diseases, metabolic disorders,
and other inflammatory demyelinating diseases.
Magnetic resonance imaging (MRI) scanning
A 1.5-T magnetic resonance imager (General Electric,
Milwaukee, WI, USA) was used to perform the brain
and spinal cord MRIs. Conventional MRI protocols were
used in all patients: T1-weighted images (T1W) with and
without gadolinium enhancement (GDE), T2-weighted
images (T2W) and fluid attenuated inversion recovery
(FLAIR). Brain MRI lesions were evaluated and definedaccording to the Paty criteria, and that described by Ito
et al. [6,21-24]. Spinal cord atrophy were evaluated ac-
cording to previous reports. Spinal cord atrophy were
evaluated and measured according to previous reports of
multiple sclerosis (MS). The whole spinal cord was
defined by using bony landmarks (foramen magnum
rostrally to the T12 vertebral body caudally). The spinal
cord was segmented into cervical and thoracolumbar
regions. and measured an upper cervical cord volume
from C2 to C3 by first measuring the cross-sectional area
of the cord at the level of the C2/C3 intervertebral disc.
Cross-sectional area was assessed at the slice above and
Figure 1 Typical brain MRI lesions in neuromyelitis optica spectrum disorders (NMOSD) with spinal cord atrophy (SCA) lesions. A-D, H:
T2 FLAIR; E-G: T2 FRFSE, A. Lesions in basal ganglia, B. Lesions in periventricular area, C. Lesions in hypothalamic region, D. Lesions in cerebellar
hemispheres, E. Lesions in midbrain aqueduct, F. Lesions in pons tegmental area, G. Lesions in the medulla oblongata (MO) and C1-2, H. Lesions
in fourth periventricle area.
Table 2 Clinical characterisation and MRI follow-up of
NMOSD patients with SCA (n = 23)





Duration of disease 0-4 y 6 2
5-9 y 5 2
10- y 5 3
Brain lesion(n)
Brain lobes 8 7
Basal ganglia 3 2
Hypothalamic and thalamic 4 2
Mesencephalon 1 1
Pons 5 3








Focal atrophy of SC 14 5
General atrophy of SC 6 3
Atrophy of STM 13 3
Atrophy of LETM 9 4
NMOSD = neuromyelitis optica spectrum disorders; SCA = spinal cord atrophy;
NMO-IgG = anti-AQP4IgG autoantibodies; LETM = longitudinally extensive
transverse myelitis; STM = shorter transverse myelitis; SC = Spinal cord.
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contiguous slices was calculated for each subject [8,9].
Longitudinally extensive transverse myelitis (LETM) is a
spinal cord lesion that extends over 3 or more vertebral
segments [6]. While shorter transverse myelitis (STM)
lesions were defined as an area extending over less than
three vertebral segments. All MRI scans were performed
prior to use of corticosteroid, immunomodulatory or
immunosuppressive treatment. An experienced neuro-
radiologist and a neurologist, both of whom were blinded
to the diagnostic categorization and the patients’ clin-
ical features. each analyzed all of the MRI scans. The
final assessments were made by consensus.
Statistical analysis
Statistical analysis was performed by SPSS version 13.0.
Values of p = 0.05 were considered statistically signifi-
cant. Categorical data were expressed as N, percentage,
and analyzed with chi-square test. Continuous data with
a normal distribution were expressed as the mean ± SD and
further analyzed with an independent 2-sample student's
t-test. Data that were not normally distributed were
analyzed by the Wilcoxon Mann–Whitney U-test.
Protocol approvals, registrations, and patient consent
The study was approved by the ethics committee of the
Third Affiliated Hospital of Sun Yat-sen University and
the informed consent was obtained from all subjects.
Results
Demographics and clinical characteristics of patients with
and without SCA in NMOSD
The clinical features of the study patients are shown in
Table 1. The age, gender, age at onset were similar in
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were found in ARR or progression index between these
two groups. The patients with SCA had longer disease
duration (p = 0.001), higher EDSS score (p = 0.001) than
those without SCA. Importantly, had a more rapid rate of
disease evolution and more severe physical disability from
the clinical onset to last visit (EDSS ≥ 6.0) (p = 0.001 and
p = 0.001, respectively). Compared to patients with the
patients without SCA, the patients with SCA more
frequently present with bowel or bladder dysfunction
(p = 0.002), movement disorders (p = 0.001), and sensory
disturbances (p = 0.027) (Figure 1).
Laboratory tests of patients with and without SCA in NMOSD
The data of laboratory tests were summarized in Table 2.
There were no significant differences in CSF, immuno-
logical indexes and other antibodies between patients
with and without SCA. However, the level of the ESR
and CRP were much higher in patients with SCA
than those without SCA (19 vs 12, p = 0.045; 2.45 vs
0.9, p = 0.001, respectively). Although significant dif-
ferences between the patients with and without SCA
existed in the positive ratio of OCB and NMO-IgG.
But, no remarkable change was observed in the two
groups (Table 3).Table 3 Biochemical values of patients with or without SCA in
NMOSD with
CSF Index WBCs (106) 7 (2–20)
Protein (0.15-0.4 mg/ml) 0.23 (0.12-0.68
Glucose (2.5-3.9 mg/ml) 3.5 (2.52-6.64)
Chloride (121.0-129.0 mg/ml) 127.6 (100.9-13
OCB (+), n (%) 0/10 (0%)
Serums Index CRP (0–6 mg/l) 2.45 (0–62.5)
ESR (0–20 mm/H) 19 (6–91)
NMO-IgG (+), n (%) 16/23 (69.6%)
ANA (+), n (%) 7/13 (53.8%)
SSA (+), n (%) 2/15 (13.3%)
SSB (+), n (%) 2/15 (13.3%)
RF (+), n (%) 5/14 (30.8%)
IgG (8–16 g/L) 12.58 (7.56-30.
IgA (0.7-3.3 g/L) 1.56 (0.19-4.59
IgM (0.5-2.2 g/L) 1.03 (0.05-1.96
C3 (0.8-1.6 g/l) 0.99 (0.13-1.66
C4 (0.1-0.4 g/l) 0.22 (0.11-0.32
CH50 (23–46 U/ml ) 37 (16–71)
NMOSD = neuromyelitis optica spectrum disorders; SCA = spinal cord atrophy; CSF =
ESR = erythrocyte sedimentation rate; NMO-IgG = anti-AQP4IgG autoantibodies; ANA
antibodies; RF = rheumatoid factor; *P < 0.05; **P < 0.01.Characteristics of brain and spinal cord lesions on MRI of
patients with and without SCA in NMOSD
The characteristics of brain and spinal cord lesions on
MRI were summarized in Table 3. Although, extensive
brain lesions were frequently involved in patients with
SCA, including brain lobes, basal ganglia, hypothalamic
and thalamic, medulla oblongata, pons, diencephalon,
lateral ventricle, third ventricle and aqueduct, and
cerebellum. However, there was no statistically sig-
nificant difference between the patients with and
without SCA (Figure 1, Tables 2 and 4).
The spinal cord lesions were predominantly located in
cervical and thoracic cord in both groups. But the ratio
of cervical cord involvement was significantly higher
in the patients with SCA than those without SCA
(p = 0.001). Furthermore, cervical and thoracic cord
lesions were more frequently found in patients with
SCA than that in the patients without SCA (p = 0.001).
Interestingly, no statistically significant difference was
noted between the two groups for the length of lesions in
cervical and thoracic cord measured by vertebral segments
(p = 0.849, p = 0.549, respectively). Moreover, the ratio of
longitudinally extensive transverse myelitis of cervical and
thoracic cord were similar in the two groups (p = 0.842,
p = 0.448, respectively) (Figure 2, Tables 2 and 4).NMOSD
SCA (n = 23) NMOSD without SCA (n = 162) P
4 (0–70) 0.807
) 0.24 (0.06-0.95) 0.395
3.28 (1.81-6.64) 0.151









36) 11.9 (1.33-33.22) 0.483
) 1.57 (0.7-4.34) 0.894
) 1.19 (0.45-6.54) 0.128
) 1.06 (0.51-2.11) 0.529
) 0.2 (0.04-1.27) 0.719
47 (10–65) 0.103
cerebrospinal fluid; OCB = oligoclonal banding; CRP = C-reactive protein;
= antinuclear antibodies; SSA = anti-SSA/Ro antibodies; SSB = anti-SSB/La
Table 4 Comparative brain and spinal cord lesions on
MRI of patients with or without SCA in NMOSD
NMOSD with
SCA (n = 23)
NMOSD without
SCA (n = 162)
P
Brain lesions, n (%)
Brain lobes 15 (65.2%) 71 (46.5%) 0.054
Basal ganglia 5 (21.7%) 26 (16%) 0.494
Hypothalamic and thalamic 6 (26.1%) 19 (11.7%) 0.059
Medulla oblongata 8 (34.8%) 31 (19.1%) 0.085
Pons 8 (34.8%) 32 (19.8%) 0.101
Mesencephalon 2 (8.7%) 6 (4.3%) 0.271
Peri-ventricleand
peri-aqueduct
7 (30.4%) 35 (21.6%) 0.344
Cerebellum 3 (13%) 8 (4.9%) 0.124
Spinal cord lesions, n (%)
Cervical cord 20 (87%) 79 (48.4%) 0.001**
Segments lesions 4.74 ± 1.91 4.65 ± 1.87 0.849
LETM 13 (56.5%) 62 (59%) 0.842
STM 10(43.5%) 32 (30.5%) 0.229
Thoracic cord 3 (13%) 62 (38.3%) 0.018*
Segments lesions 6.00 ± 3.37 5.53 ± 2.93 0.549
LETM 18 (73.9%) 67 (65.7%) 0.448
STM 6 (26.1%) 26 (24.8%) 0.894
Cervical and thoracic cord 17 (73.9%) 45 (27.8%) 0.001**
MRI =magnetic resonance imaging; SCA = spinal cord atrophy;
NMOSD = neuromyelitis optica spectrum disorders; LETM= longitudinally
extensive transverse myelitis; STM = shorter transverse myelitis;
*P < 0.05; **P < 0.01.
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Although the spinal cord lesion is widely recognized
as one of the predominant characteristics in NMOSD.
However, the SCA has only been sparsely studied,
and only focused on the locations, incidences and
magnetic resonance imaging markers of SCA in
NMOSD patients [4,11]. To the best of our knowledge,
this is the first study to investigate the clinicalFigure 2 Typical transverse myelitis (TM) and atrophy spinal cord MR
Representative MRI of four NMOSDs patients with SCA. Spinal cord MRI: sag
spinal (C2-T3)cord. B. MRI showing STM of cervical(C3)cord. C. MRI showingcharacteristics of SCA in Chinese NMOSD patients. In
the present study, we confirmed that the SCA patients
had more frequently cervical spinal cord lesions, more se-
vere clinical disability, and longer disease duration. More
importantly, our findings suggest inflammation play the
important role in the development of SCA in NMOSD.
Previous reports revealed that the frequent occurrence
of SCA in NMO patients was 52.2% or 57% [4,11], re-
spectively. However, in our study, the prevalence of SCA
was 14.2% in adult Chinese patients with NMOSD. and
SCA mainly located in the cervical spinal cord. Factors
influencing variation may include differences in disease
susceptibility, diagnostic criteria, sample size. The spinal
cord, especially the cervical cord, has been identified as
containing important ascending and descending path-
ways related to locomotion and sensation. Therefore, any
degree of SCA may be associated with the presence of
sensory, limb movements, or urinary symptoms [7,10]. In
our SCA patients, the clinical relevance of SCA in
NMOSD was supported by the difference which we found
EDSS score, particularly reaching disability milestones at
clinical onset and last visit (EDSS ≥ 6.0); the time to reach
EDSS 6.0 from onset; the more frequency and severity
of clinical presentation including bowel or bladder
dysfunction, movement disorders and sensory distur-
bances between the two group patients. Therefore, the
neurological impairment to reach EDSS ≥ 6.0; residual
EDSS score; a greater number of functional systems
involved at onset as well as higher residual deficits in
pyramidal, visual, sphincteric and sensory system, may
be the predictors of favorable SCA. Besides, disease
duration was also one of the vital factors contributing
to SCA, this suggesting a cumulative effect with time
of the pathologic processes leading to progressive and
irreversible tissue lesion in the cord [7,10].
More recent studies suggest a potential link inflamma-
tion with disease activity and clinical disability of NMO
and MS [25-27]. The C-reactive protein(CRP) is an acute
phase protein and a component of the innate immuneI lesions in neuromyelitis optica spectrum disorders (NMOSD).
ittal T2 FRFSE (A and B), T1WI (C and D). A. MRI showing LETM of
atrophy of LETM(C1- T2). D. MRI showing atrophy of STM(C2-C3).
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astrocytes [28]. it could assess the degree of inflamma-
tion, correlate with disease activity and clinical relapse in
MS and NMO [29-31]. In our study, we found CRP and
ESR in NMOSD patients with SCA were higher than
those without SCA. These suggest that the SCA patients
may have more severe systemic inflammatory reactions,
and disease activity. Moreover, dysfunction of astrocytes
occur early in NMO pathophysiological process, and
trigger demyelination, myelin loss, neuron death, and
promote SCA formation in NMOSD. Meanwhile, the
innate immune system may also play a critical role in
the initiation and progression of SCA by mediating
the demyelination of neuronal axons, and initiating a
cascade of immuno-inflammatory reactions. Although
some studies reported hypercomplementemia (serum C4,
CH50 and CSF - C5a, sC5b-9) was significantly higher in
NMO patients, especially in anti-AQP4 antibody positive
patients [32-34]. However, no significant difference was
found in complements between the two groups. And few
data showed the relationships between complements and
SCA in NMOSD. So further work is needed to determine
whether complements promotes SCA formation. AQP4
antibodies act as a radical initiator to induce the NMOSD
lesion, and consistently play an important role in the
pathological process by monitoring inflammatory tissue
injury, demyelination, necrosis and axonal damage
[35-37]. However, in the present study, there were no
differences in the seropositivity of NMO-IgG between
patients with and without SCA. So NMO-IgG might
not be associated with SCA. But, due to technical
reasons, we did not test the titer of NMO-IgG which
were thought to be related to the disease progress
and exacerbation [6,38]. However, any suggestion of a
positive link between the NMO-IgG titers and SCA
must be prompt further research using the larger, pro-
spective study design. Besides, although NMO-IgG and
systemic inflammatory reactions were closely associated
with astrocytes and involved in the pathogenesis of
NMOSD [28,39]. However, our results suggest that
they may be a two stage of the SCA disease course,
or have potential mechanisms for "cross-talk" between
the NMO-IgG and systemic inflammatory reactions.
Clearly, this study is not without limitations. Because
of the technical conditions, the titers of some autoanti-
bodies and NMO-IgG could not be tested; because only a
limited number of patients with SCA, we were not able to
make a comprehensive analysis on different anti-AQP4
antibody positive/negative of SCA.
Conclusions
The patients diagnosed as NMOSD with SCA have more
severe disability, and longer disease duration. In the early
phases of the disease, the SCA, specially concomitantcervical spinal cord lesions, may be an important indicator
of disease severity, and a limited form event of NMOSD.
Systemic inflammation occurs rapidly after the onset of
SCA, and is considered as one of the important compo-
nents of neurodegenerative processes in SCA. Thus,
early and effective inhibition of systemic microinflam-
mation is critical to prevent or minimize the develop-
ment of the SCA in NMOSD. Measurements of SCA
might help to predict disease severity and evaluate
the therapeutic effects of NMOSD.
Abbreviation
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